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ABSTRACT
Objective: The purpose of this paper is to examine
potential threats to generalisability of the results of a
multicentre randomised controlled trial using data from
A Very Early Rehabilitation Trial (AVERT).
Design: AVERT is a prospective, parallel group,
assessor-blinded randomised clinical trial. This paper
presents data assessing the generalisability of AVERT.
Setting: Acute stroke units at 44 hospitals in 8
countries.
Participants: The first 20 000 patients screened for
AVERT, of whom 1158 were recruited and randomised.
Model: We use the Proximal Similarity Model, which
considers the person, place, and setting and practice,
as a framework for considering generalisability. As well
as comparing the recruited patients with the target
population, we also performed an exploratory analysis
of the demographic, clinical, site and process factors
associated with recruitment.
Results: The demographics and stroke characteristics of
the included patients in the trial were broadly similar to
population-based norms, with the exception that AVERT
had a greater proportion of men. The most common
reason for non-recruitment was late arrival to hospital
(ie, >24 h). Overall, being older and female reduced the
odds of recruitment to the trial. More women than men
were excluded for most of the reasons, including refusal.
The odds of exclusion due to early deterioration were
particularly high for those with severe stroke (OR=10.4,
p<0.001, 95% CI 9.27 to 11.65).
Conclusions: A model which explores person, place,
and setting and practice factors can provide important
information about the external validity of a trial, and
could be applied to other clinical trials.
Trial registration number: Australian New Zealand
Clinical Trials Registry (ACTRN12606000185561) and
Clinicaltrials.gov (NCT01846247).
INTRODUCTION
Randomised controlled trials (RCTs) are the
gold standard for determining the efﬁcacy of
an intervention. In the ideal world, positive
trials lead directly to implementation of the
intervention into practice. However, trial
results are most meaningful (and useful)
when the trial has both internal and external
validity. Internal validity is well understood1
and can be controlled in the design stage of
most RCTs by using strategies such as
masking of patients and assessors, randomisa-
tion, stratiﬁcation and block randomisation
(to ensure balance between allocated
groups), and standardisation of treatment
protocols. In contrast, external validity, the
extent to which the results of a study can be
generalised to other situations and to other
people,2 is often under-recognised, under-
reported and undervalued.2–4
Rothwell5 describes the concept of external
validity as ‘slippery’ and complex, easy to
deﬁne in broad terms but problematic to
quantify. However, when the results of a
promising clinical trial are not incorporated
into practice, a commonly cited reason is a
lack of generalisability of the results.6–8 In
reality, the degree to which trial results can
Strengths and limitations of this study
▪ Use of a screening log which captured a broad
range of reasons for non-recruitment, not just
demographic data.
▪ Use of a model to explore generalisability that
goes beyond describing patient characteristics.
▪ A large, comprehensive data set relevant to
broad, pragmatic trials.
▪ A limited number of demographic and clinical
factors. Other factors may also have influenced
recruitment.
▪ Use of a large data set may demonstrate statis-
tical significance where it is of little clinical
importance.
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be generalised is often a matter of judgement, as well as
pragmatics. When it comes time to implement an inter-
vention, costs, site logistics and administrator goals play
a critical role in uptake. Nevertheless, understanding
how well the participants included in the trial are repre-
sentative of the population of interest is important,9 10
but so too is the treatment setting in which the trial took
place and the expertise of the intervention staff. It is
also important to understand whether the results can be
generalised beyond often restrictive eligibility criteria
such as age and comorbidities.11
Our aims were to examine potential threats to general-
isability of the results from an ongoing multicentre ran-
domised trial, AVery Early Rehabilitation Trial (AVERT).
AVERT is a large, pragmatic clinical trial of very early
out of bed training (mobilisation) after stroke. It takes
place in real-world clinical settings, with existing clinical
staff delivering the intervention. The inclusion criteria
are kept broad, in an effort to test whether the interven-
tion might be widely applicable to patients with stroke.9
Unlike many acute stroke trials, there is no restriction
on upper age limit or stroke subtype (infarct or haemor-
rhage), and apart from excluding patients with signiﬁ-
cant disability prior to the index stroke admission, there
is no restriction on comorbidities or previous stroke.
Although these design characteristics should enhance
the external validity of this trial, the question of how
broadly trial results can be applied more generally has
implications for implementation into practice.7 8
The Proximal Similarity Model is a useful framework
for considering different generalisability contexts.12 The
term proximal similarity was suggested by Donald T
Campbell as an appropriate relabelling of the term
external validity. Under this model, different generalis-
ability contexts, and the settings and circumstances in
which people in a study may be different from, or
similar to the population of interest, are considered and
a gradient of similarity determined. Use of this frame-
work encourages us to explore more deeply the poten-
tial critical factors that threaten external validity. For
example, in the design phase for any trial, one of the
goals is to ensure that the sample of patients involved in
the study is representative of the population of interest.
This goal is achieved by systematically addressing and,
when possible, minimising or eliminating identiﬁable
threats to external validity. Such threats can be speciﬁc
to either the patient or to the study. Patient-speciﬁc
threats include the systematic differences in important
demographic and clinical characteristics between the
patients in the study and in the population of interest.
Study-speciﬁc threats include processes and systems of
care that may or may not be encapsulated in the exclu-
sion criteria, such as when the care processes in the
study are not easily generalisable to different care sites
or care systems.7 Using the proximal similarity frame-
work, study-speciﬁc factors to consider would include
both those related to ‘place’ (site and, if relevant,
country) and to the ‘settings and practices’ (eg, Are
patients with acute stroke managed in a stroke unit or
intensive care setting?) where the trial is undertaken.
A schematic of the proximal similarity framework
applied to the AVERT context is shown in ﬁgure 1.
We aimed to (1) explore the potential threats to exter-
nal validity using data from the ﬁrst 20 000 patients
screened in AVERT and (2) examine the person, place,
and setting and practice related reasons for non-
recruitment to the trial. Our four speciﬁc objectives
were to:
1. Identify demographic and clinical differences
between the patients randomised to AVERT and the
general stroke population, using available community-
based data;
2. Identify systematic differences between person, place,
and setting and practice factors for those recruited
and those screened but not recruited;
3. Examine the reasons for non-recruitment and
explore the barriers to patient recruitment;
4. Explore whether time (both years of site involvement
in the trial and years of study overall) is associated
with differences in patient recruitment.
METHODS
Trial design in brief
AVERT (ACTRN12606000185561) is a prospective, paral-
lel group, assessor-blind, randomised, multicentre, inter-
national clinical trial that has completed the primary
outcome assessment for all randomised patients (a
longer term follow-up continues). Patients admitted to a
Figure 1 Proximal similarity framework applied to the
AVERT trial: a model for conceptualising the dimensions
along which the sample of patients may be similar to the
target population. Each dimension (person, place and setting
and practice) is affected by specific factors which may
threaten external validity (AVERT, A Very Early Rehabilitation
Trial; ICU, intensive care unit).
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stroke unit are randomised in a ratio of 1:1 to two
groups: very early and frequent mobilisation out of bed
(VEM) and usual care. The experimental intervention
(VEM) is frequent, functional, out of bed sitting, stand-
ing and walking activity starting within 24 h of stroke
onset and continued 6 days a week for 14 days or until
discharge from acute stroke care (whichever is sooner).
Patients are followed up at 3 and 12 months. The
primary outcome is the modiﬁed Rankin Scale (mRS)
score at 3 months poststroke, with secondary outcomes
for safety, walking recovery and quality of life. This
paper presents results from the ﬁrst 20 000 patients who
were screened, of whom 1158 patients were then rando-
mised to the study.
Participating hospitals
At the time of analysis, investigators from sites in
Australia, New Zealand, Malaysia, Singapore, England,
Northern Ireland, Scotland and Wales had recruited
patients to the trial. All participating sites had a dedi-
cated stroke unit with a multidisciplinary stroke team. A
detailed site questionnaire was collected from participat-
ing sites yearly. This provided a record of the number of
admissions for stroke each year and the number of
stroke beds available. Sites were classiﬁed, by investiga-
tors at each site, according to the type of stroke unit
deﬁned in the Australian National Stroke Audit, Acute
Services Organisational Survey Report:13 (1) intensive
stroke unit care model involving short stay, high nurse
patient ratio, life support facilities and no rehabilitation;
(2) acute care model involving short stays, close physio-
logical monitoring and limited rehabilitation or (3)
comprehensive model involving both acute care and a
strong rehabilitation focus, longer stays and broader
stafﬁng. Sites were also classiﬁed according to the geo-
graphic location: metropolitan (population >100 000),
regional (25 000–100 000) or rural (<25 000).13
Patient eligibility
Inclusion and exclusion criteria (ﬁgure 2) were
designed to optimise the diversity of the patients
exposed to the intervention while considering patient
safety and feasibility. There was no upper age limit for
inclusion to the study and both ischaemic and haemor-
rhagic strokes were included. Patients treated with
recombinant tissue plasmin activator (rt-PA) were eli-
gible if the attending physician allowed. Patients were
excluded if a comorbid condition (eg, lower limb frac-
ture or amputation) would prevent the start of treatment
within the ﬁrst 24 h of stroke onset or if the outcome
assessments were likely to be confounded by another
serious comorbid medical illness. Patients admitted to a
dedicated intensive care unit (ICU) are also excluded.
Screening and recruitment process
The intervention was designed to be delivered by
trained nursing and/or physiotherapy staff 6 days/week,
excluding Sunday. To meet the 24 h target for screening,
recruitment and start of intervention, screening could
take place Monday to Friday (8:00 to 17:00) and
Saturday (8:00 to 12:00) to allow for the possibility of a
recruited patient randomised to VEM on Saturday to
start training on that day. No screening was conducted
on Sundays. Screening and recruitment could be under-
taken by stroke unit nurses, physiotherapists or research
trials staff. A screening log was used to record all
patients screened for AVERT. Age, sex, stroke severity
and stroke type are important patient characteristics that
can inﬂuence outcome after stroke and are therefore
highlighted for attention on the screening logs.14 15 The
log also included reasons for exclusion as related to
either trial inclusion and exclusion criteria, or to trial
processes that might lead to exclusion (ﬁgure 2).
Recruiting staff could also list the reason for exclusion as
‘other’. This category was most commonly used for
patients who were not admitted to a stroke unit.
However, ‘other’ included patients who had a lower limb
fracture (an exclusion criterion) and instances where a
research therapist was unavailable to carry out the inter-
vention, so recruitment was not possible. Multiple
reasons could be listed for each patient. Recruiters were
required to record all stroke admissions, even those that
occurred on days or times outside of the set screening
periods.
For recruited patients, stroke severity was measured
using the National Institutes of Health Stroke Scale
(NIHSS)16 by accredited staff and then categorised into
mild (NIHSS 1–7), moderate (NIHSS 8–16) and severe
(NIHSS >16),17 which were used to stratify patients in
each group. To minimise the burden on recruiting staff,
we did not require completion of a full NIHSS on
patients who were excluded. Instead, the same trained
staff were asked to estimate whether the patient would
be likely to have an NIHSS score in the ‘mild’, ‘moder-
ate’ or ‘severe’ range.
Data management and statistical analysis
We summarised the characteristics of the participating
sites involved in the trial. Data presented include:
number of stroke admissions, number of beds and
whether the site was in a metropolitan or regional
location.
To meet the goals of objective 1, we summarised the
demographic and clinical factors from all patients with
stroke, including those who were recruited and those
screened but not recruited. We intended to compare
our data with both population-based data and data from
other acute stroke trials in which demographic data are
generally described in more detail. However, as many
acute stroke trials have pharmacological interventions,
the inclusion criteria were typically more narrow com-
pared with AVERT.18 We therefore compared demo-
graphic and clinical factors against world stroke data. We
used epidemiological data from Feigin et al,19 20 where
available, with gender and stroke severity from the
Virtual International Stroke Trials Archive (VISTA).21 We
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report 95% CIs, where available, in sample data to allow
a broad comparison with population data. Differences in
demographics between recruited versus non-recruited
patients were examined using the Wilcoxon Mann-
Whitney U test for continuous data (age) and Fisher’s
exact test for categorical data.
To explore differences between recruited and non-
recruited patients (objective 2), we systematically exam-
ined the association between patient demographic and
clinical factors (ie, age, gender, stroke severity, stroke
type) and patient recruitment or non-recruitment. We
used a random-effect multilevel logistic regression
model with patient factors as independent variables, the
recruitment status as the dependent variable, and treat-
ing site as a level variable. This enabled us to assess the
association between demographic and stroke-related
factors and the odds of recruitment in all patients. In a
second set of analyses, using the same model, we
explored each individual reason for non-recruitment in
turn. We systematically compared the recruited patients
to those not recruited due to a speciﬁc reason, and
explored demographic and clinical factors associated
with recruitment versus non-recruitment due to each
given reason (ﬁgure 3, analysis 1). We report the esti-
mated adjusted ORs of being recruited compared with
the reference of non-recruitment for each speciﬁc
reason (eg, the odds of being recruited vs non-
recruitment due to late arrival). ORs>1 indicate the
increased likelihood of recruitment and ORs<1 indicate
the increased likelihood of non-recruitment due to that
reason.
A similar random-effect multilevel logistic regression
approach was also used to more closely examine the
association between patient demographic factors and
Figure 2 Relationship between trial inclusion/exclusion criteria and screening log categories (AVERT, A Very Early
Rehabilitation Trial).
4 Bernhardt J, et al. BMJ Open 2015;5:e008378. doi:10.1136/bmjopen-2015-008378
Open Access
group.bmj.com on November 24, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
speciﬁc reasons for non-recruitment (objective 3). In
this analysis, for each reason in turn, we systematically
compared the patients not recruited due to each reason
to the patients not recruited for all other reasons com-
bined (eg, non-recruitment due to late arrival, vs non-
recruitment for all other reasons; see ﬁgure 3, analysis
2). ORs>1 indicate the increased likelihood of non-
recruitment due to a speciﬁc reason and ORs<1 indicate
the decreased likelihood of non-recruitment due to that
reason.
All statistical analyses were performed using STATA-IC.
To achieve objective 4, we examined the heterogeneity
in the individual reasons for non-recruitment between
recruiting sites and countries, as well as the effect of the
time on recruitment patterns. The between-centre and
between-country heterogeneity was estimated using
intraclass correlation coefﬁcients (ICCs) generated by
the respective random-effect logistic regression models.
In this analysis, England, Scotland, Northern Ireland
and Wales were treated as individual countries, resulting
Figure 3 Methods of explorative analysis using the first reason for non-recruitment (arrived after 24 h) as an example. Bold
boxes indicate data grouping. Analyses were repeated for all 10 reasons for non-recruitment, with four patient demographic and
clinical factors. Trial site and month of trial were controlled for in each analysis (ICU, intensive care unit; mRS, modified Rankin
Scale).
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in eight countries included in the analysis. The possible
values of ICC are between 0% and 100%. The ICC value
indicates the proportion of the variance in the propen-
sity of a speciﬁc outcome that can be attributed to sites
or countries (eg, the proportion of the variance in the
propensity of being non-recruited due to late arrival as
opposed to other reasons that can be attributed to
sites). In other words, higher values of the ICC signify
larger between-site heterogeneity and lower values are
indicative of the lower inﬂuence of site-speciﬁc or
country-speciﬁc factors on recruitment patterns.
RESULTS
Site characteristics
Of the 44 sites recruiting, most sites included were
metropolitan (n=37), with 6 regional and 1 rural. The
number of admissions per year ranged from 33 to 793.
Ward size (number of beds open at the time of review)
ranged from 8 to 77, with between 1 and 54 dedicated
stroke beds. All sites had a geographically deﬁned stroke
unit, a coordinated multidisciplinary stroke team and
access to a CT scanner, with 20 sites having onsite access
to neurosurgery. Eleven sites were classiﬁed as a
stand-alone stroke unit, whereas the majority of sites
(n=33) had dedicated stroke beds within a larger neur-
ology or mixed medical ward. One site described itself
as following an intensive care model, 22 as acute stroke
unit models and 21 as comprehensive stroke unit
models. Patients were screened between July 2006 and
December 2011.
Sample characteristics of recruited and non-recruited
patients
Table 1 presents demographic and stroke characteristics
for non-recruited and recruited patients. There was a
greater proportion of men in AVERT than in the non-
recruited patients. When we compared recruited
patients to non-recruited patients, we found that
recruited patients were signiﬁcantly younger than non-
recruited patients (p<0.001), there was a greater propor-
tion of men (p<0.001) and there were signiﬁcantly fewer
patients with severe stroke (p<0.001). The proportion of
patients with haemorrhagic stroke was not different
between the groups (p=0.504).
Baseline demographic data compared with world data
The characteristics of the recruited patients were
broadly similar to world data.19–21 In their most recent
review, Feigin et al19 identiﬁed 56 relevant studies across
28 countries (data from 1970 to 2008) totalling 37 016
strokes. The proportional frequency of stroke subtypes
(ischaemic, intracerebral haemorrhage and subarach-
noid haemorrhage) was reported for 12 242 strokes
from 18 centres, ranging from 54% to 90% for ischae-
mic stroke and 6–27% for haemorrhagic stroke. The
proportional frequency of ischaemic and haemorrhagic
strokes in the recruited patients was within these ranges
(87% and 13%, respectively). World median age was
obtained from a previous Feigin et al20 review, and was
found to be older than for the recruited patients (world
median is 75 years; recruited median is 73 years, with a
95% CI of 72 to 74). Data about the relative frequency of
stroke in women were not available from either of the
reviews by Feigin et al.19 20 However, compared to the pro-
portion of women in the VISTA database,21 there were
fewer women recruited to AVERT: world data21 indicate
46% women, compared with the recruited sample which
includes 37% women (95% CI of 34% to 40%).
Main reasons for non-recruitment
Of the 20 000 people screened, 1158 (5.8%) were
recruited. The most common reasons for non-
recruitment were arrival ‘after 24 h’ (41.9%), ‘missed’
(25.2%) and premorbid ‘mRS >2’ (disability; 12.9%;
table 2). Patients were marked as ‘missed’ if recruiting
Table 1 Baseline demographics for recruited versus non-recruited patients, including significance testing for difference
between recruited and non-recruited patients
AVERT Difference (p value)
Recruited: non recruitedNon-recruited Recruited
N (%) 18 842 (94) 1158 (6)
Age, median (IQR) 75 (64–82) 73 (63–80) <0.001
Range 15–102 18–100
Females age, median (IQR) 78 (61–80) 76 (66–82)
Males age, median (IQR) 71 (68–85) 71 (61–79)
Females % (95% CI) 47 (47 to 48) 37 (34 to 40) <0.001
NIHSS, N (%) <0.001
Mild (1–7) 10 012 (53) 619 (53)
Moderate (8–16) 4934 (26) 358 (31)
Severe (>16) 3896 (21) 181 (16)
Stroke type, N (%) 0.504
Ischaemic 16 328 (87) 1012 (87)
ICH 2514 (13) 146 (13)
AVERT, A Very Early Rehabilitation Trial; NIHSS, National Institutes of Health Stroke Scale.
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staff (predominantly ward therapists or nurses) were on
leave, unavailable or the patients arrived after hours or
on weekends, and by the time the recruiter had
returned, the patients were now outside of the 24 h
recruitment window. In total, 16.1% of reasons were
reported as ‘other’. Other was used when a patient was
deemed not suitable for reasons other than those listed
(eg, not admitted to a stroke unit, lower limb fractures)
or when no treating therapists were available to deliver
the intervention. Fewer than 1% of patients declined
participation.
Association between patient factors and the likelihood of
being recruited versus non-recruited due to a specific reason
When adjusting for the length of time the site partici-
pated in AVERT, we found that being older and female
reduced the odds of recruitment to the trial (table 3).
We then examined how these patient factors affected
the odds of recruitment relative to each reason for non-
recruitment in turn. Older patients were less likely to be
excluded because of admission to an ICU than they
were to be recruited. In contrast, they were more likely
to be excluded (than recruited) because of prior disabil-
ity, early deterioration or because they were missed.
Having an intracerebral haemorrhage meant that the
patients were less likely to be excluded (than recruited)
because they were already involved in another trial, or
had a coronary condition. In contrast, patients with
intracerebral haemorrhage were more likely to be
excluded than recruited because they deteriorated early,
failed physiological criteria or were admitted directly to
the ICU. Patients with severe strokes were more likely to
be recruited than arrive late (and be excluded). Women
were less likely to be recruited than men for all of the
exclusion criteria. In other words, they were more likely
to be excluded due to premorbid disability, a coronary
condition, early deterioration, late arrival, refusing par-
ticipation or being missed by recruiters.
Association between patient factors and the likelihood of
non-recruitment due to a specific reason versus due to other
reasons
For the third objective, we explored competing reasons
for non-recruitment and how they related to the demo-
graphic characteristics of the excluded patients (table 4).
Patients who were older, female and with severe stroke
were more likely to be excluded because of premorbid
disability (mRS≥3) and early deterioration. The odds of
exclusion due to early deterioration were particularly
high for those with severe stroke (OR=10.4, p<0.001, 95%
CI 9.27 to 11.65). Patients with haemorrhagic stroke and
severe stroke were more likely to be excluded because
they failed physiological safety criteria or were admitted
directly to the ICU. Patients with increasing age, haemor-
rhagic stroke and severe stroke were less likely to be
excluded because of late arrival at hospital (although
they could be excluded for other reasons), indicating
that they were more likely to arrive early to hospital.
Site and country variability in recruitment
Differences between the sites (44 in total) accounted for
approximately 8% of variability in the propensity to be
recruited overall (ICC=8%, 95% CI 5% to 13%), while
differences between countries (8 in total) accounted for
only 3% (ICC=3%, 95% CI 1% to 10%). Exploring the
between-site heterogeneity in recruitment patterns (see
online supplementary table S1), the highest variability
was found for non-recruitment due to the patient par-
ticipating in another trial (ICC=43%, 95% CI 28% to
59%), followed by ICU admission (ICC=26%, 95% CI
17% to 38%), and refusal to participate (ICC=23%, 95%
CI 13.7% to 36.1%). Heterogeneity by country for each
exclusion reason varied between 5% (arrival >24 h) and
24% (ICU admission).
Effect of time
There was a small decline in participation rates as the
trial progressed, with each extra month accounting for a
1% decline in the odds of recruitment (OR=0.99, 95%
CI 0.99 to 1.00, p=0.01). However, overall we found that
patient factors had a greater impact on the recruitment
patterns rather than site, country or time.
DISCUSSION
Using the proximal similarity framework approach,12 we
have explored the reasons why patients did and did not
participate in the trial, using person, place, and setting
and practice factors that might explain participation.
The most common reason for non-recruitment was late
arrival to hospital (ie, >24 h), but being older and
female also reduced the odds of recruitment to the trial.
Table 2 Reasons for non-recruitment as a percentage of
all non-recruited patients
Reason for
non-recruitment N Median % (95% CI)
After 24 h 7723 41.9 (35.1 to 49.5)
mRS≥3 3309 12.9 (9.1 to 18.4)
ICU 909 1.5 (0.8 to 2.4)
Deteriorated 1638 8.6 (6.8 to 10.2)
Coronary condition 413 1.1 (0.5 to 1.9)
Failed physiological 1239 2.7 (1.9 to 4.4)
Other trial 416 1.3 (0.4 to 2.0)
Other 4910 16.1 (13.6 to 19.3)
Refused 284 0.9 (0.6 to 1.4)
Missed 4786 25.2 (19.0 to 33.6)
Reasons are not exclusive; multiple reasons may be listed for a
single patient, and therefore sum to more than 100%. ‘Other’ was
used when a patient was deemed not suitable for reasons other
than those listed (eg, not admitted to a stroke unit, lower limb
fractures) or when no treating therapist was available. ‘Missed’
was used when recruiters were on leave, unavailable or the
patients arrived after hours or on weekends and by the time the
recruiter had returned the patients were now outside of the 24 h
recruitment window.
ICU, intensive care unit; mRS, modified Rankin Scale.
Bernhardt J, et al. BMJ Open 2015;5:e008378. doi:10.1136/bmjopen-2015-008378 7
Open Access
group.bmj.com on November 24, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
Table 3 Odds of recruitment relative to exclusion overall (for all patients screened), and odds of recruitment relative to a specific reason for non-recruitment (subgroup analysis), according to
age, gender, stroke type and severity*
Recruited versus non-recruited due to
Recruited versus
non-recruitment
(n=20 000)
After 24 h
(n=8881)
mRS≥3
(n=4467)
ICU admit
(n=2067)
Deteriorated
(n=2796)
Coronary
condition
(n=1571)
Failed
physiological
(n=2397)
Other trial
(n=1574)
Other
(n=6068)
Refused
(n=1442)
Missed
(n=5944)
Older age, years
OR 0.99 1 0.94 1.04 0.96 0.99 1 1 1 1 0.99
95% CI 0.99 to 1.00 0.99 to 1.00 0.93 to 0.94 1.03 to 1.05 0.95 to 0.97 0.98 to 1.00 0.99 to 1.01 0.99 to 1.01 0.99 to 1.00 0.99 to 1.01 0.99 to 1.00
p Value <0.01 0.37 <0.01 <0.01 <0.01 0.05 0.44 0.55 0.61 0.92 0.01
Female
OR 0.67 0.67 0.47 0.89 0.57 0.76 0.64 0.85 0.68 0.67 0.73
95% CI 0.59 to 0.76 0.59 to 0.77 0.41 to 0.56 0.69 to 1.15 0.45 to 0.72 0.58 to 0.99 0.52 to 0.79 0.65 to 1.12 0.59 to 0.78 0.50 to 0.89 0.63 to 0.84
p Value <0.01 <0.01 <0.01 0.370 <0.01 0.038 <0.01 0.251 <0.01 0.01 <0.01
Haemorrhagic stroke
OR 0.93 1.06 1.15 0.28 0.30 1.55 0.64 1.82 1.26 1.10 1
95% CI 0.77 to 1.12 0.87 to 1.29 0.90 to 1.46 0.21 to 0.38 0.23 to 0.41 1.01 to 2.37 0.49 to 0.84 1.19 to 2.79 1.02 to 1.56 0.70 to 1.74 0.81 to 1.24
p Value 0.45 0.56 0.26 <0.01 <0.01 0.04 0.001 0.01 0.03 0.68 0.97
More severe stroke
OR 0.94 1.31 0.61 0.23 0.11 0.54 0.47 0.91 1.07 1.10 1.08
95% CI 0.87 to 1.02 1.20 to 1.43 0.55 to 0.68 0.19 to 0.27 0.09 to 0.13 0.45 to 0.63 0.42 to 0.54 0.76 to 1.09 0.97 to 1.17 0.90 to 1.35 1.00 to 1.18
p Value 0.16 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 0.32 0.19 0.35 0.14
Each cell indicates whether patients with a specific demographic factor are more/less likely to be recruited rather than fall into a particular exclusion category. Scores over 1 indicate that a
patient is more likely to be recruited than be excluded for the reason identified (eg, patients with severe stroke are more likely to be recruited than arrive late), while scores under 1 indicate that a
patient is less likely to be recruited than fall into that particular exclusion category (eg, female patients are less likely to be recruited than to arrive late).
Severity of stroke is based on an NIHSS estimate of mild, moderate or severe.
Grey cells indicate OR<1, p<0.05.
Bold cells indicate OR>1, p<0.05.
*Adjusted for time (month of trial).
ICU, intensive care unit; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale.
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Table 4 Odds of exclusion for a given reason versus non-recruitment for all other reasons, according to age, gender, stroke type and severity in the non-recruited group only (N=18 842 for all
columns)*
After 24 h mRS≥3 ICU admit Deteriorated Coronary condition Failed physiological Other trial Other Refused Missed
Increasing age, years
OR 0.99 1.08 0.94 1.04 1 0.99 1 0.93 0.99 1
95% CI 0.99 to 0.99 1.07 to 1.08 0.94 to 0.95 1.03 to 1.04 0.99 to 1.01 0.99 to 1.00 0.99 to 1.00 0.86 to 0.99 0.98 to 1.00 1.00 to 1.00
p Value <0.01 <0.01 <0.01 <0.01 0.87 0.01 0.28 0.03 0.07 0.24
Female
OR 1 1.46 0.71 1.06 0.92 1.03 0.79 0.98 1.03 0.93
95% CI 0.94 to 1.07 1.34 to 1.59 0.61 to 0.83 0.94 to 1.21 0.75 to 1.13 0.91 to 1.17 0.65 to 0.97 0.92 to 1.06 0.81 to 1.31 0.86 to 0.99
p Value 0.907 <0.01 <0.01 0.33 0.44 0.62 0.026 0.62 0.81 0.03
Haemorrhagic stroke
OR 0.87 0.69 2.62 2.88 0.53 1.28 0.64 0.77 0.82 0.87
95% CI 0.79 to 0.96 0.61 to 0.79 2.23 to 3.08 2.50 to 3.32 0.38 to 0.74 1.10 to 1.49 0.46 to 0.90 0.69 to 0.86 0.55 to 1.22 0.78 to 0.97
p Value 0.01 <0.01 <0.01 <0.01 <0.01 <0.01 0.009 <0.01 0.33 0.01
More severe stroke
OR 0.59 1.50 4.34 10.39 1.69 1.95 1.01 0.86 0.76 0.80
95% CI 0.57 to 0.62 1.42 to 1.58 3.89 to 4.85 9.27 to 11.65 1.49 to 1.92 1.81 to 2.11 0.86 to 1.12 0.82 to 0.90 0.64 to 0.90 0.76 to 0.84
p Value <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 0.82 <0.001 <0.001 <0.001
Each cell indicates whether the demographic factor makes a patient more or less likely to be excluded for that particular reason. For example, for each year of age patients had an 8% increase
in the odds of having a premorbid mRS≥3.
NIHSS is an estimate, grouped by mild, moderate or severe. Stroke type could be either ischaemic or haemorrhagic.
Grey cells indicate OR<1, p>0.05.
Bold cells indicate OR>1, p>0.05.
*Adjusted for time.
ICU, intensive care unit; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale.
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Our ﬁndings indicate that women had much greater
odds of premorbid disability, were more likely to arrive
late to hospital, were more likely to have early deterior-
ation and fail the physiological safety criteria. The odds
of exclusion due to early deterioration were particularly
high for those with severe stroke. When looking at the
between-site heterogeneity in the reasons for non-
recruitment, the variability was highest for participation
in another trial, admission to ICU and refusal to partici-
pate. These observations ﬁt with expected variations in
trial activity given that sites are likely to have different
competing trials, different ICU admission protocols and
different trials experience.
The lower proportion of women recruited to this trial
is consistent with the acute stroke trials literature.21–23
Sex disparities in stroke epidemiology, pathophysiology,
treatment and outcomes are well documented in the
stroke literature.24 25 Stroke affects a greater number of
women in old age,25 largely because women have
greater longevity and stroke which more commonly
occurs in older people. Women are also more likely to
be disabled at the time of their stroke.26 27 Previous
stroke disability is a major reason for exclusion from this
study for the pragmatic need to optimise the number of
patients able to contribute to the primary outcome,
independence (score 0–2) on the mRS. While the inter-
vention (rehabilitation) could potentially be suitable or
even beneﬁcial for patients with pre-existing disability,
the chance of a participant with premorbid disability
moving from being disabled (mRS>2) to having a good
outcome is low. Our observation that women tended to
have a delayed arrival to hospital has been reported in a
number of studies examining prehospital delay,
although this is not a uniform ﬁnding.28 The most
common explanation for this delayed arrival time is that
more women than men live alone in older age and
arrival times are faster when a stroke is witnessed by
another person.25 It is also possible that poorer recruit-
ment of women reﬂects an unconscious bias on the part
of the recruiter, in favour of recruiting men.
Nevertheless, we have found signiﬁcant relationships
that help to explain the phenomenon.
In many acute stroke trials, intracerebral haemorrhage
is an exclusion criterion.21 In the VISTA trials data-
base,29 6% of patients have haemorrhagic stroke, which
is at the lower limit of estimates for the proportion of
stroke due to haemorrhage from international epi-
demiological data.19 We were pleased to note that this
group was well represented in our trial. Once again,
where these patients were excluded, the reasons for
their exclusion were strongly aligned with what we
already know about this stroke subgroup: early deterior-
ation, failed physiological criteria and ICU admission.
The sudden onset of the haemorrhage is often dramatic,
resulting in rapid transport to hospital (ie, they are less
likely to arrive within 24 h poststroke). Patients with
intracerebral haemorrhage often experience early
deterioration within hours of stroke and have greater
mortality. Therefore, it is not uncommon for these
patients to be managed in the ICU rather than on the
general stroke unit.30 Patients with intracerebral haemor-
rhage were also less likely to be excluded because of a
coronary condition and less likely to be recruited to
another trial, again consistent with current
evidence.23 31
One of the unexpected barriers to recruitment to this
trial has been the signiﬁcant proportion of patients who
were ineligible because they arrived late to hospital.
This, rather than clinical characteristics of potential
patients, was the major barrier. This should be consid-
ered a modiﬁable exclusion variable. Delay in hospital
admission has implications for delivery of proven stroke
therapies such as thrombolysis. There were surprisingly
few data from sources, such as local stroke registries or
large clinical trials, with a 24 h window, to inform our
estimates. Studies of thrombolysis, often from single
centres, indicated that between 25% and 59% of
patients arrive within 3 h of stroke, with older age, ethni-
city and gender (females) inﬂuencing arrival time.32
The large proportion of patients delaying arrival to hos-
pital resulted in the need to enrol a larger number of
trial sites than originally planned, and this, in turn,
extended the duration of the trial. Fortunately, the dur-
ation of a site’s participation in the trial appeared to
have little impact on the reasons for exclusion and vari-
ability between sites was generally low. When variation
was observed by site (eg, ICU admission greater in some
centres than others), it was easily explained by different
care models and processes across the participating hospi-
tals. For example, in some hospitals, it is routine for
patients experiencing severe stroke to be admitted to
the ICU, while in most hospitals these patients will be
managed in the stroke unit. Variability in recruitment to
other trials is also readily explained by the fact that
some teaching hospitals conduct a large number of
trials, while in smaller sites, AVERT was the only active
trial in the stroke unit.
The strengths of our study include a large, inter-
national data set, collected over several years, that is rele-
vant to the conduct of broad, pragmatic trials. Second,
we have used a conceptual framework12 to explore a
broader range of factors than those commonly exam-
ined in reports of external validity.4 We believe that this
analytic approach shows promise and encourages a
more in-depth exploration of the reasons why different
patients are excluded. In the case of AVERT, with the
exception of delayed arrival to hospital, most exclusions
appeared to be a direct consequence of the trial ques-
tion or related safety concerns.
The main weakness of our study is that, as a conse-
quence of this being a large pragmatic trial, we have
relatively limited information on each patient screened
for eligibility for inclusion in the trial. Further, screen-
ing log data were only checked against source data at
site visits, which occurred on average once per year.
The data manager monitored variations in screening
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log data on a more regular basis directly with site inves-
tigators, and all noted variations were followed up.
Data were collected by different staff across eight coun-
tries, although all used the same standardised data col-
lection form for screening. It is also important to
remember that a large data set may demonstrate statis-
tical signiﬁcance where it is of little practical
importance.33
A common complaint of clinicians is uncertainty
about the external validity of trial results.2 7 8 Our
understanding of the external validity of RCTs could be
improved by routine and standardised exploration of the
critical drivers of exclusion from trials in different set-
tings and conditions. In the current CONSORT state-
ment, external validity is discussed, but there are no
clear recommendations for reporting.3 If an agreed
framework for examining external validity could be
found, standard recommendations could form part of
future CONSORT statements, thereby increasing the
practical value of clinical trial data reported.
CONCLUSION
In this study using data obtained in AVERT, we have
demonstrated that a model of exploring generalisability
that considers people, places and processes of care can
provide important information about the external valid-
ity of a trial. This approach could be applied to other
trial populations, but trialists would need to identify and
plan for the collection of appropriate variables.
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